Manju Sengar

Oct 2, 2023 | thelancet.com | Christopher M. Booth |Manju Sengar |Aaron Goodman

We appreciate the Correspondences from Nicolas André and Yakup Ergun on our Comment on the Common Sense Oncology (CSO) movement. 1Booth CM Sengar M Goodman A et al. Common Sense Oncology: outcomes that matter. Lancet Oncol. 24: 833-835Nicolas André makes the important point that although the specific challenges in paediatric oncology might differ from adult oncology, the principles of CSO are just as valid. We completely concur with this sentiment.

May 10, 2023 | ecancer.org | Manju Sengar |Wilma M Hopman |Ghulam Rehman Mohyuddin |Aaron Goodman

How likely is this article to improve patient care in your region? Is reading this article likely to improve your clinical practice? How likely are you to recommend this article to a colleague?

May 10, 2023 | ecancer.org | Manju Sengar |Wilma M Hopman |Ghulam Rehman Mohyuddin |Aaron Goodman

Background: Design, results, and interpretation of oncology randomised controlled trials (RCTs) have changed substantially over the past decade. In this study, we describe all RCTs evaluating anticancer therapies in haematological cancers published globally during 2014–2017 with comparisons with solid tumours RCTs. Methods: A PubMed literature search identified all phase 3 RCTs of anticancer therapy for haematological cancers and solid tumours published globally during 2014–2017.